No material signal from this insider cluster. The small dollar amounts and pattern of option exercises followed by sales suggest routine liquidity management. Monitor for upcoming clinical catalysts or partnership announcements as the primary drivers for NRIX.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Aug 5 $25.12entry
- T+1 · 3mo ago +0.40%α +0.56% · $25.22
- T+5 · 3mo ago +6.01%α +5.66% · $26.63
- T+20 · due 3mo ago Pending
- T+60 · due 19d ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three C-suite insiders at Nurix Therapeutics (CSO, CLO, CFO) sold a total of $461K in open-market shares over a 7-day window, representing just 0.02% of the $2.4B market cap. The sales are trivial in size and appear liquidity-driven following option exercises, providing no material signal about the company's outlook.
Key Financial Metrics
Key Facts
- Total open-market insider sales: $461,000 across 3 C-suite executives (CSO, CLO, CFO)
- Sales represent 0.02% of Nurix's $2.4B market cap, well below the 0.1% materiality threshold
- Multiple derivative exercises (non-cash) preceded the sales, consistent with routine option exercise and tax-covering or diversification
- Prior insider activity (30d) shows 6 sells totaling $665K, indicating ongoing but modest selling patterns
Financial Impact
Trivial insider sales totaling $461K, representing 0.02% of market cap.
Risk Factors
- None from this filing, insider activity is immaterial in size and context
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1785927676296 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $15.48 +2.04% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $15.48 +0.45% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $15.48 +4.31% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $15.48 +4.31% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $15.48 +4.31% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $15.48 −2.95% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $15.48 +2.95% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $15.48 −40.05% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $15.48 −40.05% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers